MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

All articles tagged: Opioid dependence with unspecified opioid-induced disorder (F11.29)

HealthDay 08 July at 09.36 PM

Acupuncture Can Reduce Methadone Dose, Opioid Craving

For individuals with opioid use disorder receiving methadone maintenance treatment (MMT), eight weeks of acupuncture is superior to sham acupuncture for reducing methadone dose and opioid craving, according to a study published online July 9 in the Annals of Internal Medicine.Liming Lu, M.D., from the Guangzhou University of Chinese Medi

HealthDay 08 January at 04.56 PM

Mindfulness-Oriented Recovery Enhancement Boosts Methadone Treatment

Telehealth-delivered mindfulness-oriented recovery enhancement (MORE) is a feasible and effective adjunct to methadone treatment (MT) for individuals with opioid use disorder (OUD) and pain, according to a study published online Dec. 7 in JAMA Psychiatry.Nina A. Cooperman, Psy.D., from Rutgers Robert Wood Johnson Medical School in P

HealthDay 08 January at 04.56 PM

Mindfulness-Oriented Recovery Enhancement Boosts Methadone Treatment

Telehealth-delivered mindfulness-oriented recovery enhancement (MORE) is a feasible and effective adjunct to methadone treatment (MT) for individuals with opioid use disorder (OUD) and pain, according to a study published online Dec. 7 in JAMA Psychiatry.Nina A. Cooperman, Psy.D., from Rutgers Robert Wood Johnson Medical School in P

HealthDay 02 January at 11.50 PM

Personalized Protocol Cuts Opioid Prescribing After C-Section

A personalized protocol for opioid prescriptions after cesarean delivery reduces the median morphine milligram equivalents prescribed at discharge, according to a study recently published in the American Journal of Obstetrics & Gynecology.Chinonye S. Imo, M.D., from Parkland Health in Dallas, and colleagues examined whether a transi

HealthDay 21 December at 11.17 PM

FDA Approves DNA Cheek Swab Test to ID Patients at High Risk for Opioid Addiction

The U.S. Food and Drug Administration has approved a first-of-its-kind test -- the AvertD test -- that uses DNA swabbed from a patient's cheek to determine if they have a combination of genetic variants associated with an elevated risk for opioid addiction.The 15 genetic variants detected by the test are involved in the brain reward pathways t